Revenue GrowthA sustained doubling of revenue from 2020 to 2025 demonstrates scalable commercial execution and expanding market penetration across branded formulations, exports and APIs. This durable top-line momentum supports reinvestment in distribution, registrations and product development over the next 2–6 months.

Improved Gross MarginA materially higher gross margin (59.08% in 2025) indicates better manufacturing efficiency, pricing power or a favorable product mix. Higher gross margins provide a structural buffer to absorb SG&A or R&D investment and support longer-term margin expansion even if operating leverage is gradual.

Low Leverage / Strong EquityA conservative capital structure and rising equity provide financial flexibility to fund regulatory approvals, capex and geographic expansion without heavy reliance on external debt. Low leverage reduces bankruptcy risk and supports durable investment capacity over months ahead.

Bears Say

Negative Operating & Free Cash FlowNegative operating and free cash flows in 2025 signal weak cash conversion despite revenue growth. Persisting cash deficits can constrain working-capital cycles, limit self-funded growth or force external financing, making the business more sensitive to funding conditions over the coming months.

Modest Net ProfitabilityA net margin near 6.5% implies limited retained earnings relative to sales, reducing the cushion for price or input-cost shocks. With modest bottom-line conversion, sustained investments or one-time costs can materially depress earnings, slowing durable improvement in shareholder returns.

Volatile Operating MarginsVolatility in EBIT/EBITDA margins points to inconsistent operational execution, product mix swings or cost variability. Such volatility undermines predictability of cash generation and planning, increasing execution risk for international launches and manufacturing scale-up over the medium term.

Unichem Laboratories Limited News

Unichem Laboratories Settles European Commission Fine

Unichem Laboratories Limited ( ($IN:UNICHEMLAB) ) has shared an update. Unichem Laboratories Limited has announced the payment of...

5M ago

Unichem Laboratories Faces Demand Notice from NPPA for Alleged Overcharging

The latest update is out from Unichem Laboratories Limited ( ($IN:UNICHEMLAB) ). Unichem Laboratories Limited has received a...

6M ago

Unichem Laboratories Receives USFDA Inspection Report

Unichem Laboratories Limited ( ($IN:UNICHEMLAB) ) just unveiled an announcement. Unichem Laboratories Limited announced that it has received...

7M ago

Unichem Laboratories Updates RTA Contact Details

Unichem Laboratories Limited ( ($IN:UNICHEMLAB) ) has provided an announcement. Unichem Laboratories Limited announced a change in the...

11M ago

UNICHEMLAB FAQ

What was Unichem Laboratories Limited’s price range in the past 12 months?

Unichem Laboratories Limited lowest stock price was ₹304.25 and its highest was ₹727.95 in the past 12 months.

What is Unichem Laboratories Limited’s market cap?

Unichem Laboratories Limited’s market cap is ₹22.59B.

When is Unichem Laboratories Limited’s upcoming earnings report date?

Unichem Laboratories Limited’s upcoming earnings report date is May 21, 2026 which is in 62 days.

How were Unichem Laboratories Limited’s earnings last quarter?

Unichem Laboratories Limited released its earnings results on Feb 05, 2026. The company reported ₹37.538 earnings per share for the quarter, beating the consensus estimate of N/A by ₹37.538.

Is Unichem Laboratories Limited overvalued?

According to Wall Street analysts Unichem Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Unichem Laboratories Limited pay dividends?

Unichem Laboratories Limited pays a Annually dividend of ₹4 which represents an annual dividend yield of N/A. See more information on Unichem Laboratories Limited dividends here

What is Unichem Laboratories Limited’s EPS estimate?

Unichem Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Unichem Laboratories Limited have?

Unichem Laboratories Limited has 70,405,754 shares outstanding.

What happened to Unichem Laboratories Limited’s price movement after its last earnings report?

Unichem Laboratories Limited reported an EPS of ₹37.538 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.969%.

Which hedge fund is a major shareholder of Unichem Laboratories Limited?

Currently, no hedge funds are holding shares in IN:UNICHEMLAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Unichem Laboratories Limited

Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. It offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management; and active pharmaceutical ingredients, as well as contract manufacturing services. The company was founded in 1944 and is headquartered in Mumbai, India.